LIfT BioSciences

Executive Summary

LIfT BioSciences is a preclinical-stage biotechnology company pioneering the world's first neutrophil-based cell therapy platform. Its allogeneic Immuno-Modulating Alpha Neutrophils (IMANs) are designed to treat a range of solid tumors by modulating the tumor microenvironment. Unlike conventional T-cell therapies, neutrophils offer unique advantages such as inherent tumor trafficking, lack of graft-versus-host disease, and potential for off-the-shelf use. The company is based in London, UK, and is currently advancing its lead candidate toward clinical trials. While still in early development, LIfT's differentiated approach addresses key limitations of current cell therapies and could unlock a new class of immunotherapies. The platform's allogeneic nature further enhances scalability and cost-effectiveness, positioning LIfT as a potential innovator in the competitive cell therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026IND/CTA Submission for Lead IMAN Program70% success
• Q4 2026Phase 1 Interim Safety and Efficacy Data40% success
• TBDStrategic Partnership or Licensing Deal50% success